Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.
|Original language||English (US)|
|Number of pages||10|
|Journal||Urologic Oncology: Seminars and Original Investigations|
|State||Published - Jul 2003|
- LHRH agonist
ASJC Scopus subject areas